"Bleomycin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2. It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors.
| Descriptor ID |
D001761
|
| MeSH Number(s) |
D09.400.420.110 D12.644.233.110
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Bleomycin".
Below are MeSH descriptors whose meaning is more specific than "Bleomycin".
This graph shows the total number of publications written about "Bleomycin" by people in this website by year, and whether "Bleomycin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 5 | 5 |
| 1995 | 2 | 2 | 4 |
| 1996 | 4 | 2 | 6 |
| 1997 | 1 | 1 | 2 |
| 1998 | 4 | 4 | 8 |
| 1999 | 1 | 6 | 7 |
| 2000 | 0 | 4 | 4 |
| 2001 | 0 | 3 | 3 |
| 2002 | 1 | 9 | 10 |
| 2003 | 1 | 3 | 4 |
| 2004 | 1 | 4 | 5 |
| 2005 | 1 | 7 | 8 |
| 2006 | 1 | 8 | 9 |
| 2007 | 1 | 2 | 3 |
| 2008 | 2 | 6 | 8 |
| 2009 | 0 | 2 | 2 |
| 2010 | 4 | 6 | 10 |
| 2011 | 0 | 3 | 3 |
| 2012 | 0 | 10 | 10 |
| 2013 | 2 | 4 | 6 |
| 2014 | 2 | 10 | 12 |
| 2015 | 0 | 8 | 8 |
| 2016 | 1 | 7 | 8 |
| 2017 | 0 | 7 | 7 |
| 2018 | 0 | 9 | 9 |
| 2019 | 2 | 4 | 6 |
| 2020 | 1 | 4 | 5 |
| 2021 | 0 | 9 | 9 |
| 2022 | 1 | 10 | 11 |
| 2023 | 0 | 8 | 8 |
To return to the timeline,
click here.
Below are the most recent publications written about "Bleomycin" by people in Profiles.
-
Impact of cumulative dose of brentuximab vedotin on outcomes of frontline therapy for advanced-stage Hodgkin lymphoma. Blood Adv. 2023 12 26; 7(24):7485-7493.
-
Tuftelin1 drives experimental pulmonary fibrosis progression by facilitating stress fiber assembly. Respir Res. 2023 Dec 17; 24(1):318.
-
Single-Cell RNA Sequencing Provides New Insights into Therapeutic Roles of Thyroid Hormone in Idiopathic Pulmonary Fibrosis. Am J Respir Cell Mol Biol. 2023 10; 69(4):456-469.
-
Real-World Use of Positron Emission Tomography-Computed Tomography and Reported Deauville Scores in Advanced-Stage Classic Hodgkin Lymphoma: A Community Oncology Practice Perspective. JCO Oncol Pract. 2023 Oct; 19(10):860-870.
-
Estimating long-term outcomes in classic Hodgkin lymphoma: a United States population-based oncology simulation model based on overall survival from the ECHELON-1 trial. Leuk Lymphoma. 2023 05; 64(5):1017-1025.
-
Real-World Patient Characteristics, Treatment Patterns, and Outcomes for Patients With Stage III or IV Classic Hodgkin Lymphoma Treated With Frontline ABVD: A Retrospective Database Review in the United States. Clin Lymphoma Myeloma Leuk. 2023 07; 23(7):527-534.
-
Endothelial cell-derived MMP19 promotes pulmonary fibrosis by inducing E(nd)MT and monocyte infiltration. Cell Commun Signal. 2023 03 13; 21(1):56.
-
microRNA-33 deficiency in macrophages enhances autophagy, improves mitochondrial homeostasis, and protects against lung fibrosis. JCI Insight. 2023 02 22; 8(4).
-
Saracatinib, a Selective Src Kinase Inhibitor, Blocks Fibrotic Responses in Preclinical Models of Pulmonary Fibrosis. Am J Respir Crit Care Med. 2022 12 15; 206(12):1463-1479.
-
Fenbendazole Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice via Suppression of Fibroblast-to-Myofibroblast Differentiation. Int J Mol Sci. 2022 Nov 15; 23(22).